Possibilities for preventive and personalized therapy of cancer by drugs screening

OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-24 ⓘ

This study developed a thiol-disulfide system screening method to personalize treatments for endometriosis and cancer, demonstrating improved therapeutic efficacy and reduced adverse effects through biomarker-guided drug selection.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-24 · read from full text ⓘ

This study developed a drug screening method based on the thiol-disulfide system to predict therapeutic efficacy and safety across various diseases. Researchers analyzed blood samples from over 1,200 patients with conditions including chronic hepatitis C, viral infections, endometriosis, and several types of cancer using spectrophotometry to measure SH- and SS-groups. The results indicated that this biomarker approach significantly improved treatment outcomes for endometriosis by doubling efficiency in hormonal therapy compared to standard protocols, while also enhancing responses in hepatitis C and non-small cell lung cancer. Relevance to endometriosis: explicitly studied as one of the conditions treated with personalized hormonal therapy, demonstrating a two-fold increase in treatment efficiency when guided by the thiol-disulfide biomarker test.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,371 characters · extracted from pmc-nxml · 1 sections · click to expand

Section

The purpose of this study was the search of new biomarkers for preventive and personalized therapy of cancer. Thiol-disulfide system was selected as a target for drug screening as the most important biochemical system that characterizes the state of the antioxidant defense and redox processes. The study involved more than 1,200 patients with chronic hepatitis C (HCV), genital herpes, human papillomavirus infection, endometriosis, non-small cell lung cancer (NSCLC), metastatic kidney and prostate cancer. An original method for screening drug preparations was proposed, where whole blood with anticoagulant (EDTA) was incubated in thermostat (37°C) in the presence of drugs for 1 h, the control samples incubated with saline [ 1 ]. Determination of SH-and SS-groups in hemolysate was done by spectrophotometry. In processing the data performance SH-groups and SH/SS ratio in the control and experimental samples were compared. It was found that all medications, including cytostatic, hormonal, antiviral and immune have either a stimulating or a depressing effect on blood thiol-disulfide system, by which one can predict the efficacy and safety of therapy, and to individualize treatment [ 2 - 4 ]. In two controlled studies a 3-fold increase in the incidence of virological response of personalized monotherapy with interferon (IFN) of HCV patients was shown, and the rate of adverse effects was decreased by 6 times compared with standard IFN therapy. Prognostic significance of SH/SS -test for the treatment of HCV patients was 89.8% [ 3 ]. Control studies also demonstrated a 2-fold increase in the efficiency of personalized hormonal therapy of endometriosis compared with standard and a 2-fold increase in the frequency of partial remission rate of NSCLC after personalized treatment by cytostatics compared with standard chemotherapy [ 4 ]. Thus, the thiol-disulfide system can be regarded as a universal biomarker for preventive and personalized therapy of cancer. The proposed method of drugs screening using SH/SS-test can be used to personalize therapy of viral diseases and cancer by hormonal, antiviral, cytostatic and immune preparations to improve efficiency and overcome resistance to drugs, finding the best drugs, their doses and combinations, reducing the frequency of side effects and complications to prevent cancer, its relapse and progression.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
unpaywall
last seen: 2026-08-12T06:43:03.944938+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC